Dr. Neil J. Korman, MD

Medicare patients and services

Medicare patients, 2024

264

Services billed

1,213

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 87 payments worth $90,822 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Ohio →

Industry-funded research

Named as a principal investigator on 18 industry-funded studies in 2025, from 5 companies. The companies reported $777,135 in research payments for these studies, mostly to the institutions running them.

• A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
  Eli Lilly and Company · Completed · NCT06046729
• A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
  Incyte Corporation
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
  Eli Lilly and Company · Recruiting · NCT05723198
• A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Contro…
  Amgen Inc.
• A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
  Incyte Corporation
• A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis
  Incyte Corporation
• A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study investigating the efficacy safety and tolerability of ritlecitinib in adult and adolescent participants with non segmental vitiligo
  Pfizer Inc.
• A phase 3 randomized withdrawal and doseup titration multicenter extension study investigating the safety efficacy and tolerability of ritlecitinib in adult and adolescent participants with nonsegmental vitiligo
  Pfizer Inc.
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
  Eli Lilly and Company · Completed · NCT04392154
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
  Eli Lilly and Company · Completed · NCT06588283

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Cleveland

• Mandy Alhajj, DO
• Antoine Amado De Olazaval, M.D.
• John S. Anthony, M.D.
• Olivia Arballo, D.O.
• Joshua Arbesman, M.D.
• Phillip L. Bailin, MD
• Danny Barlev, M.D
• Elma D. Baron, MD